Title |
The role of delamanid in the treatment of drug-resistant tuberculosis
|
---|---|
Published in |
Therapeutics and Clinical Risk Management, May 2015
|
DOI | 10.2147/tcrm.s71076 |
Pubmed ID | |
Authors |
Joseph M Lewis, Derek J Sloan |
Abstract |
Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 43% |
Germany | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 57% |
Practitioners (doctors, other healthcare professionals) | 3 | 43% |
Mendeley readers
The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
Unknown | 146 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 20 | 14% |
Student > Master | 20 | 14% |
Student > Bachelor | 19 | 13% |
Other | 10 | 7% |
Researcher | 8 | 5% |
Other | 20 | 14% |
Unknown | 51 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 18% |
Biochemistry, Genetics and Molecular Biology | 17 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 13 | 9% |
Chemistry | 13 | 9% |
Agricultural and Biological Sciences | 7 | 5% |
Other | 15 | 10% |
Unknown | 57 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2015.
All research outputs
#7,791,459
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#398
of 1,308 outputs
Outputs of similar age
#85,759
of 279,338 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#15
of 42 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,338 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.